AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Evofem's Hormone-Free Contraceptive PHEXXI Seeks UAE Approval
ByAinvest
Tuesday, Jun 24, 2025 7:30 pm ET1min read
Evofem Biosciences announced that Pharma 1 Drug Store LLC has filed an application with the UAE Ministry of Health and Prevention seeking approval for the commercialization of PHEXXI, Evofem's FDA-approved hormone-free contraceptive. Market research indicates growing demand for hormone-free, on-demand contraception in the UAE and surrounding region. Evofem plans to launch PHEXXI in the UAE as quickly as possible following approval.
Title: Pharma 1 Submits PHEXXI Marketing Application in the UAEEvofem Biosciences, Inc. (OTCPK: EVFM) announced that Pharma 1 Drug Store LLC has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval for the commercialization of PHEXXI, Evofem's FDA-approved hormone-free contraceptive [1]. The application marks a significant milestone in Evofem's global expansion strategy.
PHEXXI, the first and only locally-acting contraceptive gel approved by the U.S. Food and Drug Administration (FDA), is applied zero-to-60 minutes before intercourse using a pre-filled applicator. It works by maintaining the normal vaginal microbiome with a pH inhospitable to sperm and certain pathogens [1].
Market research indicates growing demand for hormone-free, on-demand contraception in the UAE and the surrounding region. Pharma 1 plans to launch PHEXXI in the UAE in the first quarter of 2026, following regulatory approval [2]. Pharma 1 holds exclusive commercialization rights for PHEXXI in the Middle East, including the UAE, Kuwait, Saudi Arabia, Qatar, and certain other countries in the licensed region [1].
Evofem CEO Saundra Pelletier expressed optimism about the potential for PHEXXI in the UAE market, stating, "We look forward to expanding and diversifying our revenue stream with PHEXXI sales to Pharma 1 for the UAE beginning in July 2025..." [2].
Pharma 1 is responsible for obtaining and maintaining any regulatory approvals required to market and sell PHEXXI, and will handle all aspects of distribution, sales, and marketing in these countries [1].
References:
[1] https://www.prnewswire.com/news-releases/evofems-phexxi-submitted-for-marketing-approval-in-united-arab-emirates-by-pharma-1-drug-store-302487645.html
[2] https://www.nasdaq.com/articles/evofem-biosciences-says-pharma-1-applies-marketing-approval-phexxi-uae
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet